A71 - Abraxane monotherapy in patients with advanced breast cancer: evaluation of efficacy and tolerability in our clinical practice

Abstract

Introduction: Abraxane is an anticancer agent approved for the treatment of metastatic breast cancer. Abraxane is a colloidal suspension of paclitaxel and human serum albumin that can be administered without premedication, it is able to improve overall response rate and time to progression in patients with progressive metastatic breast cancer.This study reports efficacy and safety in patients treated with abraxane in our center.Materials and methods: We analized retrospectively 31 patients treated with abraxane from January 2012 to February 2015 Abraxane 260 mg/m2 was administered every three weeks. The main characteristics of patients were as follow: median age 58,12 years (range:36-77), performance status 0-2 (ECOG), estrogen positive disease 83,8% and progesterone positive 71%. Seven patients were HER 2 positive. Three/thirty-one patients had only bony metastases, 8/31 patients had only visceral metastases, 20 women had visceral and bony disease. Nine/thirty-one patients received treatment by 3 line, 16/31 patients were on 4-5 line, 6/31 patients received treatment over 5 line. Median number of cycles received was 2,16 ( range 1-12)Results: Patients receiving abraxane had a median overall survival of 10,22 months and a progression free survival of 4,45 months. A partial response was seen in 19,3% of cases and a stable disease in 38,7% of cases. ORR was 58 %. Fatigue was the most commonly reported toxicity, being reported in approximately 77,42% of patients.Other adverse events included: febrile neutropenia 41,93%, neurosensory toxicity 19,35%, anemia 9,68%, vomiting 3,23%.Conclusions: We conclude that our experience on real life confirm the tolerability and the efficacy of abraxane in women with metastatic breast cancer. Introduction: Abraxane is an anticancer agent approved for the treatment of metastatic breast cancer. Abraxane is a colloidal suspension of paclitaxel and human serum albumin that can be administered without premedication, it is able to improve overall response rate and time to progression in patients with progressive metastatic breast cancer. This study reports efficacy and safety in patients treated with abraxane in our center. Materials and methods: We analized retrospectively 31 patients treated with abraxane from January 2012 to February 2015 Abraxane 260 mg/m2 was administered every three weeks. The main characteristics of patients were as follow: median age 58,12 years (range:36-77), performance status 0-2 (ECOG), estrogen positive disease 83,8% and progesterone positive 71%. Seven patients were HER 2 positive. Three/thirty-one patients had only bony metastases, 8/31 patients had only visceral metastases, 20 women had visceral and bony disease. Nine/thirty-one patients received treatment by 3 line, 16/31 patients were on 4-5 line, 6/31 patients received treatment over 5 line. Median number of cycles received was 2,16 ( range 1-12) Results: Patients receiving abraxane had a median overall survival of 10,22 months and a progression free survival of 4,45 months. A partial response was seen in 19,3% of cases and a stable disease in 38,7% of cases. ORR was 58 %. Fatigue was the most commonly reported toxicity, being reported in approximately 77,42% of patients. Other adverse events included: febrile neutropenia 41,93%, neurosensory toxicity 19,35%, anemia 9,68%, vomiting 3,23%. Conclusions: We conclude that our experience on real life confirm the tolerability and the efficacy of abraxane in women with metastatic breast cancer.